With the background of the recent rally, we are moving this auto play to a ‘HOLD’ so you don’t enter at high valuations.
Prime Stock alert: Moving this auto play to a HOLD again Read More »
Assessing management quality is a key input to screening stocks and R Balakrishnan gives us some red flags to watch out for while doing this.
17 Red flags to watch out for when assessing management quality Read More »
Recent announcements relating to ownership change in this pharma stock prompt us to move this stock from a ‘BUY’ to a ‘HOLD’.
Prime Stock alert: Moving this pharma stock to a HOLD Read More »
A report from Kotak Institutional Equities sparked a bout of selling in mid and small caps. Should you be concerned? Here is what we think.
Mid and small cap stocks – is it time to exit? Read More »
Results update for 5 of our Prime Stocks.
Results update 3 – for quarter ending June 2023 Read More »
This commodity stock is well placed to play the changing tide in the sector on account of its affordable valuations.
Prime Stock Recommendation: Play the rising tide in this sector Read More »
Consolidation and correction have made stocks of affordable housing finance companies attractive and this is our pick in the space.
Prime Stock Recommendation: An affordable housing finance stock at affordable valuation Read More »
results update for 5 of our Prime Stocks
Results update 1 – for quarter ending June 2023 Read More »
What stock markets should be assessed on, where markets stand now, and other observations.
There is greed in the air Read More »
We are moving an industrial sector stock that we recommended in June 2022, to a HOLD.
Prime Stock alert: Moving this tonnage stock to a HOLD Read More »
We are moving this Prime Stock to a HOLD and this report will explain why.
Prime Stock alert: Moving this healthcare play to a HOLD on swift up move Read More »
We think the time is right to partially sell your holdings of this API maker and hold the rest.
Book profits and HOLD stocks of this API maker Read More »
The purpose of these disclosures is to provide essential information about the Research Services in a manner to assist and enable the prospective client/client in making an informed decision for engaging in Research services before onboarding. History, Present business and Background: PrimeInvestor Financial Research Private Limited is registered with SEBI as Research Analyst with registration no. INH200008653. The Research Analyst got its registration on August 19, 2021 and is engaged in offering research and recommendation services. Terms and conditions of Research Services: The Research Services will be limited to providing independent research recommendation and shall not be involved in any advisory or portfolio allocation services. The Research Analyst never guarantees the returns on the recommendation provided. Investor shall take note that Investment/trading in stocks/Index or other securities is always subject to market risk. Past performance is never a guarantee of same future results. The Research Analyst shall not be responsible for any loss to the Investors. Disciplinary history: There are no pending material litigations or legal proceedings against the Research Analyst. As on date, no penalties / directions have been issued by SEBI under the SEBI Act or Regulations made there under against the Research Analyst relating to Research Analyst services. Details of its associates: No associates. Disclosures with respect to Research and Recommendations Services: The Research Analyst or its directors or any of its officer/employee does not trade in securities which are subject matter of recommendation. There are no actual or potential conflicts of interest arising from any connection to or association with any issuer of products/ securities, including any material information or facts that might compromise its objectivity or independence in the carrying on of Research Analyst services. Such conflict of interest shall be disclosed to the client as and when they arise. Research Analyst or its directors or its employee or its associates have not received any compensation from the company which is subject matter of recommendation. Research Analyst or its directors or its employee or its associates have not managed or co-managed the public offering of any company. Research Analyst or its directors or its employee or its associates have not received any compensation for investment banking or merchant banking of brokerage services from the subject company. Research Analyst or its directors or its employee or its associates have not received any compensation for products or services other than above from the subject company. Research Analyst or its directors or its employee or its associates have not received any compensation or other benefits from the Subject Company or 3rd party in connection with the research report/ recommendation. The subject company was not a client of Research Analyst or its directors or its employee or its associates during twelve months preceding the date of recommendation services provided. Research Analysts or its directors or its employee or its associates has not served as an officer, director or employee of the subject company. Research Analysts has not been engaged in market making activity of the subject company.
Full disclosures and disclaimers
Compliance Officer Details: Name: Srikanth Meenakshi; Email: contact@primeinvestor.
Grievance Officer Details: Name: Srikanth Meenakshi; Email: contact@primeinvestor.
